ABL Texcell Diagnostics' 2026 half-year report is now available.

ABL Texcell Diagnostics, a company active in the field of molecular diagnostics and listed on Euronext Paris, has published its half-year financial report for the period ending June 30, 2026. This document is available on the company's website in the dedicated section. At the Board of Directors meeting on September 8, 2026, the half-year financial statements were approved by the auditor without any comments regarding their accuracy. No significant discrepancies were noted compared to the results previously published.

ABL Texcell Diagnostics markets molecular biology solutions and has recently expanded its activities by integrating virology-related services. It relies on a broad sales network to distribute its products, particularly in microbiology.